Uncover Overlooked Insights on Ventas (VTR)

By Kim Brooks • Thursday, May 01 15:14 • Permanent Link

One of the losers of today's trading session was Ventas. Shares of the Specialty real estate investment trust company plunged -5.8%, and some investors may be wondering if its price of $66.05 would make a good entry point. Here's what you should know if you are considering this investment:

Ventas has moved 51.6% over the last year, and the S&P 500 logged a change of 10.0%
VTR has an average analyst rating of buy and is -12.92% away from its mean target price of $75.84 per share
Its trailing earnings per share (EPS) is $0.32
Ventas has a trailing 12 month Price to Earnings (P/E) ratio of 206.4 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $0.16 and its forward P/E ratio is 412.8
The company has a Price to Book (P/B) ratio of 2.6 in contrast to the S&P 500's average ratio of 4.74
Ventas is part of the Real Estate sector, which has an average P/E ratio of 27.31 and an average P/B of 1.94
Ventas, Inc. (NYSE: VTR) is a leading S&P 500 real estate investment trust enabling exceptional environments that benefit a large and growing aging population. With approximately 1,350 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy. The Company's growth is fueled by its over 800 senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. The Ventas portfolio also includes outpatient medical buildings, research centers and healthcare facilities. The Company aims to deliver outsized performance by leveraging its unmatched operational expertise, data-driven insights from its Ventas OI platform, extensive relationships and strong financial position. Ventas's seasoned team of talented professionals shares a commitment to excellence, integrity and a common purpose of helping people live longer, healthier, happier lives.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.